ENXTPA:SANPharmaceuticals
Is Sanofi (ENXTPA:SAN) Undervalued After Halting Amlitelimab Development?
Why the amlitelimab decision matters for Sanofi shareholders
Sanofi (ENXTPA:SAN) is halting development of amlitelimab for moderate to severe atopic dermatitis after a pipeline review concluded the efficacy and safety profile did not justify regulatory submissions compared with current treatments.
The company cited long term phase 3 data showing maintained clinical response and an emerging safety profile, yet still judged amlitelimab would not offer a meaningful improvement over existing...